• Home
  • Politics
  • Health
  • World
  • Business
  • Finance
  • Tech
  • More
    • Sports
    • Entertainment
    • Lifestyle
What's Hot

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

May 29, 2025

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Saturday, May 31
Patriot Now NewsPatriot Now News
  • Home
  • Politics

    Security video shows brazen sexual assault of California woman by homeless man

    October 24, 2023

    Woman makes disturbing discovery after her boyfriend chases away home intruder who stabbed him

    October 24, 2023

    Poll finds Americans overwhelmingly support Israel’s war on Hamas, but younger Americans defend Hamas

    October 24, 2023

    Off-duty pilot charged with 83 counts of attempted murder after allegedly trying to shut off engines midflight on Alaska Airlines

    October 23, 2023

    Leaked audio of Shelia Jackson Lee abusively cursing staffer

    October 22, 2023
  • Health

    Disparities In Cataract Care Are A Sorry Sight

    October 16, 2023

    Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

    October 16, 2023

    Long-term steroid use should be a last resort

    October 16, 2023

    Rite Aid Files For Bankruptcy With More ‘Underperforming Stores’ To Close

    October 16, 2023

    Who’s Still Dying From Complications Related To Covid-19?

    October 16, 2023
  • World

    New York Democrat Dan Goldman Accuses ‘Conservatives in the South’ of Holding Rallies with ‘Swastikas’

    October 13, 2023

    IDF Ret. Major General Describes Rushing to Save Son, Granddaughter During Hamas Invasion

    October 13, 2023

    Black Lives Matter Group Deletes Tweet Showing Support for Hamas 

    October 13, 2023

    AOC Denounces NYC Rally Cheering Hamas Terrorism: ‘Unacceptable’

    October 13, 2023

    L.A. Prosecutors Call Out Soros-Backed Gascón for Silence on Israel

    October 13, 2023
  • Business

    EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

    May 29, 2025

    ‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

    May 29, 2025

    DeSantis Signs Bill Making Gold And Silver Legal Tender

    May 28, 2025

    John Deere Announces $20 Billion Plan To Build Up American Manufacturing

    May 28, 2025

    EV Startup Promised To Cut China Ties — Then Reportedly Shared US Data Anyway

    May 27, 2025
  • Finance

    Ending China’s De Minimis Exception Brings 3 Benefits for Americans

    April 17, 2025

    The Trump Tariff Shock Should Push Indonesia to Reform Its Economy

    April 17, 2025

    Tariff Talks an Opportunity to Reinvigorate the Japan-US Alliance

    April 17, 2025

    How China’s Companies Are Responding to the US Trade War

    April 16, 2025

    The US Flip-flop Over H20 Chip Restrictions 

    April 16, 2025
  • Tech

    Cruz Confronts Zuckerberg on Pointless Warning for Child Porn Searches

    February 2, 2024

    FTX Abandons Plans to Relaunch Crypto Exchange, Commits to Full Repayment of Customers and Creditors

    February 2, 2024

    Elon Musk Proposes Tesla Reincorporates in Texas After Delaware Judge Voids Pay Package

    February 2, 2024

    Tesla’s Elon Musk Tops Disney’s Bob Iger as Most Overrated Chief Executive

    February 2, 2024

    Mark Zuckerberg’s Wealth Grew $84 Billion in 2023 as Pedophiles Target Children on Facebook, Instagram

    February 2, 2024
  • More
    • Sports
    • Entertainment
    • Lifestyle
Patriot Now NewsPatriot Now News
Home»Health»Gene Therapies For Retinal Disorders
Health

Gene Therapies For Retinal Disorders

June 22, 2023No Comments6 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Gene Therapies For Retinal Disorders
Share
Facebook Twitter LinkedIn Pinterest Email

Eye Series Photo – Futuristic Eye

ACCESS Health International

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision.

In 1999, I defined regenerative medicine as the collection of interventions that restore to normal function tissues and organs that have been damaged by disease, injured by trauma, or worn by time. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

Gene therapy can potentially address a wide range of acute and chronic diseases. The application of gene therapy to restoring vision has been especially fruitful. Here we discuss the potential of gene therapy to address macular degeneration. According to the World Health Organization (WHO), age-related macular degeneration affects over 196 million people globally. The incidence of the disease will likely increase in the coming years as a consequence of aging populations in many countries.

ADVERTISEMENT

These findings have prompted researchers to develop intervention strategies based on individual polygenic risk scores. However, interpreting these scores at a personal level may be challenging. As a result, more traditional approaches to gene therapy and gene editing have been considered for age-related macular degeneration.

Gene Therapy & Gene Editing: Two Effective Tools for Addressing Deleterious Genes

Gene therapy and gene editing are two different approaches to treating genetic mutations. Gene therapy replaces a defective gene with a functional one through a delivery vector. Gene editing, on the other hand, involves manipulating the target gene at the DNA or genomic level. CRISPR-based gene technologies permit both substitution of entire genes and the editing of small region target sequences. CRISPR-based treatments have been studied for retinal disorders such as retinitis pigmentosa.

ADVERTISEMENT

Over the past five decades, gene therapy has evolved from a simple concept to the subject of over 1400 clinical trials across the globe, offering a degree of innovation and intervention never seen before. More particularly, viral vector gene therapy has emerged as an innovative treatment option for retinal diseases such as wet and dry age-related macular degeneration, paving the way for revolutionary treatment plans that could significantly improve patient outcomes.

What Are Vectors For Gene Therapy?

In gene therapy, a vector is a vehicle that delivers therapeutic genes or nucleic acids to target cells to treat genetic disorders or diseases. Typically, vectors can be divided into two categories, viral and nonviral vectors. Viral vectors utilize modified viruses to deliver the desired gene to the target cells. In contrast, nonviral vectors use alternative methods to provide genes to target cells.

ADVERTISEMENT

Messenger RNA (mRNA) has emerged as a nonviral gene therapy vector that shows promising potential in inducing cellular and therapeutic immune responses. Through its versatile protein delivery mechanism and dendritic cells’ potent antigen-presenting abilities, mRNA can deliver genetic information to treat various inherited and acquired diseases. mRNA is also often used alongside CRISPR for retinal disorders, cancer treatment, and other CAR T therapies.

The inability to integrate into the host genome and the strictly transient expression are additional benefits that make mRNA therapy a promising avenue for safe and effective gene therapy. However, viral vectors often have greater efficiency in transferring genes to target cells than nonviral vectors, and researchers have therefore been working on modifying viral vectors to reduce the risks involved in their use in human subjects.

The concept of using viruses as vectors dates back to the 1970s. However, it wasn’t until the 1980s that scientists could manipulate viral genomes without adverse effects. Recently, the spotlight has fallen on adeno-associated viral, or AAV, vectors. AAVs are a class of small DNA viruses that infect humans and other primates without causing illness. These developments have enabled new applications in gene therapy, with their use surging in clinical trials.

ADVERTISEMENT

Scientific research has discovered that in mouse muscle tissue, in vivo administration of AAV vectors can provide long-term transgene expression and effective relief. By requiring a helper virus to replicate, AAV vectors present a significant advantage because they are unlikely to be associated with a disease. Thus, essential proteins coding for viral replication and integration can be removed from the AAV genome.

Moreover, AAV vectors have demonstrated a capacity to elicit a relatively mild immune response, mitigating the chance of producing a host immune response while substantially decreasing the overall vector dose required for therapeutic efficacy. This lessened risk inherent in AAV vector therapeutics makes them particularly promising for clinical trial exploration.

A Landmark for Retinal Gene Therapy

ADVERTISEMENT

The suitability of eyes as targets for gene therapy stems from the fact that individual genes are responsible for different conditions, making it possible to replace a single gene to minimize payload delivery for AAV vectors and avoid potential errors arising from large transgenes. Furthermore, the potential of a single gene therapy dose presents a marked improvement over frequent intravitreal injections to treat retinal diseases.

One of the landmark breakthroughs in gene therapy occurred when three clinical trials evaluated the efficacy of adeno-associated virus serotype 2 vectors carrying a functional copy of the retinal pigment epithelium-specific 65-kDa protein gene, or RPE65. This gene encodes the RPE65 protein, critical in the biological conversion of light photons into electrical signals transmitted to the brain via the optic nerve.

This groundbreaking research led to the FDA’s approval of the first-ever ocular gene therapy: Voretigene Neparvovec-rzyl, also called Luxturna. Spark Therapeutics develops Luxturna to treat confirmed cases of inherited retinal dystrophy caused by RPE65 mutations. Approved by the United States Food & Drug Administration in December 2017, Luxturna is a one-time subretinal injection of a functional copy of the RPE65 gene that becomes transduced into the retinal cells.

ADVERTISEMENT

The injection of Luxturna delivers a functional copy of the RPE65 gene to the retinal cells, allowing the production of RPE65-specific protein, which is crucial for the retinoid cycle. By restoring the retinoid process, Luxturna aims to improve vision and preserve existing vision. Today, Luxturna is being administered at ten treatment centers in the United States, and it remains a significant breakthrough in gene therapy.

Since the approval of Luxturna, other clinical trials evaluating gene therapies have reported positive results, indicating that gene therapy could revolutionize age-related macular degeneration treatment plans.

To learn more about the eye, read more stories at www.williamhaseltine.com

ADVERTISEMENT

See also  Scientists inch closer to single-shot gene editing for blood disorders
disorders Gene Retinal Therapies
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Boosting Confidence And Wellness: Modern Therapies And Techniques

July 25, 2024

Personality Disorders In Teens: Signs, Symptoms And Treatment

July 19, 2024

Understanding And Managing Mood Disorders: When To Seek Help

June 26, 2024

5 Alternative Therapies For Managing Stress And Anxiety

February 29, 2024
Add A Comment

Leave A Reply Cancel Reply

Top Posts

GOP Scam Crumbles As FBI Doc Does Not Say Biden Received A Bribe

June 8, 2023

Marjorie Taylor Greene Slammed Over ‘Seceding’ Message

September 12, 2023

Slower, but still strong US employment growth expected in July

August 4, 2023

Rudy Giuliani Is Reportedly Melting Down And Drinking Heavily As He Fears Indictment

June 26, 2023
Don't Miss

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

Business May 29, 2025

Consumers’ Research issued a “Woke Alert” on Thursday warning American shoppers that three European companies…

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025

John Deere Announces $20 Billion Plan To Build Up American Manufacturing

May 28, 2025
About
About

This is your World, Tech, Health, Entertainment and Sports website. We provide the latest breaking news straight from the News industry.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest
Categories
  • Business (4,136)
  • Entertainment (4,220)
  • Finance (3,202)
  • Health (1,938)
  • Lifestyle (1,645)
  • Politics (3,084)
  • Sports (4,036)
  • Tech (2,006)
  • Uncategorized (4)
  • World (3,944)
Our Picks

California, New York Attorneys General Investigating Woke NFL for ‘Workplace Discrimination’

May 7, 2023

Costco Q4 earnings top estimates as high gas prices fuel foot traffic

September 26, 2023

Help now, or pay more later when it fails

April 26, 2023
Popular Posts

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

May 29, 2025

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025
© 2025 Patriotnownews.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.